Lista de obras - Lorenzo Falchi - Dominio Público Uruguay

A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy

artículo científico publicado en 2007

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.

artículo científico publicado en 2017

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma

scientific article published on 23 May 2018

An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients

scientific article published on 09 December 2011

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

artículo científico publicado en 2016

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

artículo científico publicado en 2017

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia

artículo científico publicado en 2016

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial

artículo científico publicado en 2017

Bullet 'manicure': does lead prevent hydroxyurea-induced cutaneous toxicity? ⬇️

artículo científico publicado en 2014

Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center

artículo científico publicado en 2013

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia

artículo científico publicado en 2014

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

artículo científico publicado en 2009

ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant

artículo científico publicado en 2014

Eosinophilia in Hematologic Disorders

artículo científico publicado en 2015

Glucocorticoid-induced activation of caspase-8 protects the glucocorticoid-induced protein Gilz from proteasomal degradation and induces its binding to SUMO-1 in murine thymocytes

artículo científico publicado en 2010

High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

artículo científico publicado en 2016

High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience

artículo científico publicado en 2012

Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.

artículo científico publicado en 2017

Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia

artículo científico publicado en 2016

Kit Mutations: New Insights and Diagnostic Value

artículo científico publicado en 2018

Maesopsin 4-O-β-D-Glucoside, a Natural Compound Isolated from the Leaves ofArtocarpus tonkinensis, Inhibits Proliferation and Up-Regulates HMOX1, SRXN1 and BCAS3 in Acute Myeloid Leukemia ⬇️

artículo científico publicado el 1 de junio de 2011

New Therapeutic Approaches in Polycythemia Vera

artículo científico publicado en 2015

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

artículo científico publicado en 2016

Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies

artículo científico publicado en 2019

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

artículo científico publicado en 2019

Rapid and sustained response of an intra- and extracranial large cell lymphoma mass to liposomal intrathecal Ara-C and R-MegaCEOP systemic chemotherapy

artículo científico publicado en 2009

Severe mechanical hemolysis in a patient with thalassemia minor who had undergone inappropriate splenectomy

artículo científico publicado en 2016

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

artículo científico publicado en 2013

Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution

artículo científico publicado en 2010

The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience

artículo científico publicado en 2015

The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience

article

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.

artículo científico publicado en 2017

The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.

artículo científico publicado en 2017

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas

artículo científico publicado en 2012

Tyrosine Kinase Inhibitors

artículo científico publicado en 2010

Lista de obras de Lorenzo Falchi

A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma

An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial

Bullet 'manicure': does lead prevent hydroxyurea-induced cutaneous toxicity? ⬇️

Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant

Eosinophilia in Hematologic Disorders

Glucocorticoid-induced activation of caspase-8 protects the glucocorticoid-induced protein Gilz from proteasomal degradation and induces its binding to SUMO-1 in murine thymocytes

High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience

Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.

Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia

Kit Mutations: New Insights and Diagnostic Value

Maesopsin 4-O-β-D-Glucoside, a Natural Compound Isolated from the Leaves ofArtocarpus tonkinensis, Inhibits Proliferation and Up-Regulates HMOX1, SRXN1 and BCAS3 in Acute Myeloid Leukemia ⬇️

New Therapeutic Approaches in Polycythemia Vera

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

Rapid and sustained response of an intra- and extracranial large cell lymphoma mass to liposomal intrathecal Ara-C and R-MegaCEOP systemic chemotherapy

Severe mechanical hemolysis in a patient with thalassemia minor who had undergone inappropriate splenectomy

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution

The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience

The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.

The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas

Tyrosine Kinase Inhibitors